Chronic heart failure: prevention and treatment options
The problem of chronic heart failure remains relevant today. According to the Age of CHF study, the prevalence of this disease in this country is 12%. In 66% of cases CHF has ischemic etiology. Rational approach to treatment and evaluation of all possible risks significantly improves patient's...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2013-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/842 |
id |
doaj-1cfdfdff4da5403eaaee6048e9885fa6 |
---|---|
record_format |
Article |
spelling |
doaj-1cfdfdff4da5403eaaee6048e9885fa62021-07-28T13:29:12ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902013-12-0101-2566310.21518/2079-701X-2013-1-2-56-63842Chronic heart failure: prevention and treatment optionsS. B. Migutina0State Clinical Hospital No. 60, MoscowThe problem of chronic heart failure remains relevant today. According to the Age of CHF study, the prevalence of this disease in this country is 12%. In 66% of cases CHF has ischemic etiology. Rational approach to treatment and evaluation of all possible risks significantly improves patient's condition and reduces severity of the disease. Non-drug treatments include low-salt diet and physical rehabilitation based on balanced aerobic activity.Despite a huge list of drugs recommended and used at CHF, attention to medicines called myocardial cytoprotectors remains high.https://www.med-sovet.pro/jour/article/view/842хроническая сердечная недостаточностьпрофилактикалечениемиокардиальные цитопротекторыheart failurepreventiontreatmentmyocardial cytoprotectors |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
S. B. Migutina |
spellingShingle |
S. B. Migutina Chronic heart failure: prevention and treatment options Медицинский совет хроническая сердечная недостаточность профилактика лечение миокардиальные цитопротекторы heart failure prevention treatment myocardial cytoprotectors |
author_facet |
S. B. Migutina |
author_sort |
S. B. Migutina |
title |
Chronic heart failure: prevention and treatment options |
title_short |
Chronic heart failure: prevention and treatment options |
title_full |
Chronic heart failure: prevention and treatment options |
title_fullStr |
Chronic heart failure: prevention and treatment options |
title_full_unstemmed |
Chronic heart failure: prevention and treatment options |
title_sort |
chronic heart failure: prevention and treatment options |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2013-12-01 |
description |
The problem of chronic heart failure remains relevant today. According to the Age of CHF study, the prevalence of this disease in this country is 12%. In 66% of cases CHF has ischemic etiology. Rational approach to treatment and evaluation of all possible risks significantly improves patient's condition and reduces severity of the disease. Non-drug treatments include low-salt diet and physical rehabilitation based on balanced aerobic activity.Despite a huge list of drugs recommended and used at CHF, attention to medicines called myocardial cytoprotectors remains high. |
topic |
хроническая сердечная недостаточность профилактика лечение миокардиальные цитопротекторы heart failure prevention treatment myocardial cytoprotectors |
url |
https://www.med-sovet.pro/jour/article/view/842 |
work_keys_str_mv |
AT sbmigutina chronicheartfailurepreventionandtreatmentoptions |
_version_ |
1721274795938545664 |